Biosion, Inc. Appoints Anthony Yeh, Ph.D., as Chief Strategy Officer and Head of China BD

Newark, DE, U.S. and Nanjing, China – January 3, 2022.  Biosion, Inc. (“Biosion”), a global clinical stage biotechnology company, today announced the appointment of Dr. Anthony Yeh to the position of Chief Strategy Officer and Head of China business development (BD), where he will lead corporate strategy, China BD, and capital fundraising. He will report to Dr. Mingjiu Chen, Chief Executive Officer (CEO). Prior to joining Biosion, Dr. Yeh was most recently Vice President, Head of Corporate Strategy, Investor Relations and Capital Market at CStone Pharmaceuticals (HKSE:2616).

“We are pleased to welcome Anthony to Biosion as we continue to expand globally and strengthen our executive leadership,” said Dr. Mingjiu Chen, Founder, Chairman and CEO of Biosion. “With the unique combination of cross-cultural background, outstanding scientific training, and extensive experience in the biopharma industry, Anthony represents the next generation of leaders who are the driving force for the globalization of China-based innovation. We look forward to his leadership as we advance toward our vision of delivering breakthrough biologics to patients worldwide.”

“Since I came back to China in 2007, China’s biopharmaceutical industry has undergone a momentus shift, from biosimilar-focused into one that nurtures innovation, and from domestic-focused into one that pivots towards globalization,” said Dr. Yeh. “Based on its global development capabilities, proprietary discovery platforms, and rich pipeline of innovative biologics, Biosion is becoming the front runner leading the next wave of China biopharmaceutical industry evolution. I look forward to joining Biosion’s world-class team to expand its global partnerships and accelerate global capital access.”

Dr. Yeh brings to Biosion over 15 years of experience in healthcare, investment, and management consulting. During his tenure at CStone Pharmaceuticals (HKSE: 2616), Dr. Yeh served several different leadership roles in helping to build CStone through public listing and eventually to commercialization stage. Prior to CStone, Dr. Yeh was Regional Head of Business Economics and Strategy at Abbott (NYSE: ABT) and engagement manager at L.E.K. Consulting where he specialized in life sciences strategy and M&A. Dr. Yeh holds a Ph.D. in Molecular Medicine from University of Oxford and a Bachelor of Science (honors) from Queensland University of Technology.

About Biosion, Inc.

Biosion is a global clinical stage biotechnology company developing innovative biologics to address resistant, relapsed and residual disease for patients worldwide. Established in 2017, Biosion has assembled a world-class team with extensive global biologics development experience, and built an oncology and auto-immune focused pipeline of innovative biologics through its internally-derived proprietary technologies, including the H³ antibody discovery platform, SynAb™synergistic antibody platform, SynTracer™ HT-endocytosis platform, and Flexibody™ bispecific platform and external source of innovation. The lead asset BSI-045B (anti-TSLP mAb) is currently in a global phase I clinical trial, with multiple assets expected to reach the clinic in 2022. Biosion has operations in the US, Australia and China. The mission of Biosion is to discover and develop innovative biologics through the synergy of great science, cutting-edge technologies and superior craftmanship for patients worldwide.

Biosion has global collaborations with Celldex (NASDAQ:CLDX), Chiatai Tianqing (CTTQ, subsidiary of Sino Biopharm, HK:1177) and OBI Pharma (TWO:4174), and is actively seeking global partners who are interested in licensing, partnership or co-development opportunities. For more information and full pipeline details, please visit www.biosion.com.

Biosion, Inc. Licenses BSI04702, An Anti-TROP-2 mAb, to OBI Pharma, Inc. for Worldwide Development and Commercialization Rights as an Antibody Drug Conjugate and Other Derivative Products

This license agreement continues to build on Biosion’s efforts to create and develop meaningful biologics to treat resistant, relapsed and residual disease for patients worldwide.

Newark, DE, USA, Nanjing, China – December 13, 2021.  Biosion, Inc. (“Biosion”), a global, clinical stage biotech company announced today that OBI Pharma Inc. (4174.TWO) (“OBI Pharma”) and Biosion have signed an exclusive license agreement providing OBI Pharma worldwide rights, excluding China to Biosion’s proprietary anti-Trop2 humanized monoclonal antibody, BSI04702. The license agreement enables OBI Pharma to conduct further preclinical and clinical development, registration, and commercialization of BSI04702 as an Antibody Drug Conjugate and other derivative products. Under the terms of the agreement, OBI Pharma will pay license fees to Biosion, including an upfront payment, future development milestones and net sales royalties.  The specific terms of the agreement were not disclosed.

“The licensing of our anti-TROP-2 mAb to OBI Pharma for global development further exhibits the strength of our Discovery engine and proprietary SynTracerTM HT-endocytosis platform to identify superior mAbs, ideal as ADCs” said Dr. Hugh Davis, Chief Operations Officer of Biosion, Inc. and President of Biosion USA.  “We are looking forward to partnering with OBI Pharma to advance BSI-04702 into the clinic and making a difference for patients worldwide.”

BSI04702 is an anti-TROP2 humanized monoclonal antibody with differentiated properties relative to existing mAbs that bind TROP-2.  It was created through Biosion’s proprietary Discovery engine and SynTracerTM HT-endocytosis Platform.

About Biosion, Inc.

For more information and full pipeline details, please visit www.biosion.com.

About OBI Pharma , Inc.

For more information and full pipeline details, please visit www.obipharma.com.

Media and Investor Contact:

Frank Liu, Ph.D.

Senior Director, Business Development

Biosion USA, Inc.

Phone: +1-302-998-5126

E-mail: Frank.Liu@Biosion.com

Biosion, Inc. Completed Pre-B+ Round Financing to Accelerate the Discovery and Global Development of Its Innovative Biologics Pipeline

New funding will strengthen Biosion’s “In Global For Global” positioning by accelerating its clinical pipeline and expanding its global biologics development teams

Newark, DE, Nanjing CN – Dec 9, 2021. Biosion Inc. (“Biosion”), a global, clinical-stage biotech company, today announced completion of a 200 million RMB preB+ financing round (including preB 2nd tranche financing) to accelerate discovery and global development of its innovative biologics portfolio targeting immunologic and cancer diseases. The financing was led by 3E Bioventures Capital, joined by Chase Capital. Concurrent with the financing, Mr. Lei Liu, the Director of 3E Bioventures Capital will join Biosion’s Board of Directors. Index Capital acts as the sole financial advisor for the current round of financing.

 “We are pleased to welcome 3E Bioventures Capital – a prestigious professional bio-venture capital firm – to join our effort in building our differentiated preclinical and clinical development portfolio, our global biologics development team and to further enable our strategy to be a leading “In Global For Global” biotech company” said Dr. Mingjiu Chen, Founder, Chairman and CEO of Biosion.

Dr. Karen Liu, Partner of 3E Bioventures Capital, said: “We believe GLOBALIZATION is the big theme for the next generation of biopharma. The capability of accessing a global talent pool, leveraging territorial clinical resources, and navigating through regional regulatory barriers is key to translating novel science from concept to product. We are excited and confident that Biosion is on the launchpad to lead this wave of industry change with its world-class leadership team.”

Through recent significant enhancement of the Executive Leadership team, Advisory Board and Global Development team, Biosion is now poised to substantially accelerate global clinical development efforts of its innovative biologics pipeline.

About Biosion, Inc.

Biosion is a leading “In Global For Global” clinical stage biotechnology company developing innovative biologics to address resistant, relapsed and residual disease for patients worldwide. Established in 2017, Biosion has assembled a world-class team with extensive experience in global biologics development and built an oncology and auto-immune focused pipeline of innovative biologics through its internally-derived proprietary technologies, including the H3 hybridoma platform, SynAbTM synergistic antibody platform, SynTracerTM HT-endocytosis screening platform, and FlexibodyTM bispecific platform. Biosion’s mission is to discover and develop innovative biologics through the synergy of great science, cutting edge technologies and superior craftmanship for patients worldwide. Biosion is actively seeking global partners who are interested in licensing, partnership or co-development opportunities. For more information and full pipeline details, please visit www.biosion.com.

About 3E Bioventures Capital

3E Bioventures Capital is dedicated to investing in cutting-edge life sciences and biomedical technologies, with a focus on breakthrough first-in-class therapies and disruptive cross-disciplinary innovations in medical devices and diagnostics. 3E Bioventures takes on a science-driven, entrepreneur-friendly investment philosophy by working closely with companies and research institutions to develop drugs or products that have strong unmet medical needs. With offices in Beijing, Shanghai, and the San Francisco Bay Area, 3E Bioventures leverages its experience, capabilities, and network to help companies tap into markets and resources across the Pacific and advance with greater speed and capital efficiency. The motto of 3E Bioventures Capital is captured in its name 3E: Expertise, Efficiency, Execution.

About Chase Capital

Chase Capital is a professional investment institution focusing on early to mid-stage equity investment, with a core focus on two emerging industries, including biopharmaceutical and technology innovation. The funds managed by Chase Capital are mainly RMB funds and have invested in and incubated more than 20 domestic and foreign innovative companies, including HuiYu Pharmaceutical (688553), Harbour Biomed (02142) Elpiscience, Ab&b Bio-Tech, and other leading companies. With offices in Nanjing and Suzhou, Chase Capital focuses on the Yangtze River Delta region. Adhering to the concept of “focus on professionalism and accompany growth”, we hope to provide multi-faceted services for each partner company and help them grow into leading companies in the industry, as well as providing long-term development space and value recognition for investors and company partners.

Close Bitnami banner
Bitnami